450 related articles for article (PubMed ID: 15316510)
1. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein.
Zhang K; Kepley CL; Terada T; Zhu D; Perez H; Saxon A
J Allergy Clin Immunol; 2004 Aug; 114(2):321-7. PubMed ID: 15316510
[TBL] [Abstract][Full Text] [Related]
2. Modifications to an Fcgamma-Fcvarepsilon fusion protein alter its effectiveness in the inhibition of FcvarepsilonRI-mediated functions.
Allen LC; Kepley CL; Saxon A; Zhang K
J Allergy Clin Immunol; 2007 Aug; 120(2):462-8. PubMed ID: 17543377
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the use of genetically engineered negative signaling molecules to treat allergic diseases.
Saxon A; Zhu D; Zhang K; Chan LA; Kepley CL
Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2006; (95):223-31; discussion 231-3. PubMed ID: 17393744
[TBL] [Abstract][Full Text] [Related]
4. An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotype inhibits basophil degranulation through cross-linking of FcepsilonRI with FcgammaRIIb.
Wigginton SJ; Furtado PB; Armour KL; Clark MR; Robins A; Emara M; Ghaemmaghami AM; Sewell HF; Shakib F
Clin Exp Allergy; 2008 Feb; 38(2):313-9. PubMed ID: 18070161
[TBL] [Abstract][Full Text] [Related]
5. A bispecific antibody against human IgE and human FcgammaRII that inhibits antigen-induced histamine release by human mast cells and basophils.
Tam SW; Demissie S; Thomas D; Daëron M
Allergy; 2004 Jul; 59(7):772-80. PubMed ID: 15180766
[TBL] [Abstract][Full Text] [Related]
6. Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb.
Cemerski S; Chu SY; Moore GL; Muchhal US; Desjarlais JR; Szymkowski DE
Immunol Lett; 2012 Mar; 143(1):34-43. PubMed ID: 22305932
[TBL] [Abstract][Full Text] [Related]
7. A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases.
Mertsching E; Bafetti L; Hess H; Perper S; Giza K; Allen LC; Negrou E; Hathaway K; Hopp J; Chung J; Perret D; Shields M; Saxon A; Kehry MR
J Allergy Clin Immunol; 2008 Feb; 121(2):441-447.e5. PubMed ID: 17949802
[TBL] [Abstract][Full Text] [Related]
8. FcepsilonRI-alpha siRNA inhibits the antigen-induced activation of mast cells.
Safaralizadeh R; Soheili ZS; Deezagi A; Pourpak Z; Samiei S; Moin M
Iran J Allergy Asthma Immunol; 2009 Dec; 8(4):177-83. PubMed ID: 20404387
[TBL] [Abstract][Full Text] [Related]
9. Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases.
Saxon A; Zhu D; Zhang K; Allen LC; Kepley CL
Curr Opin Allergy Clin Immunol; 2004 Dec; 4(6):563-8. PubMed ID: 15640700
[TBL] [Abstract][Full Text] [Related]
10. Does IgE bind to and activate eosinophils from patients with allergy?
Kita H; Kaneko M; Bartemes KR; Weiler DA; Schimming AW; Reed CE; Gleich GJ
J Immunol; 1999 Jun; 162(11):6901-11. PubMed ID: 10352312
[TBL] [Abstract][Full Text] [Related]
11. Assessment of three human FcepsilonRI-transfected RBL cell-lines for identifying IgE induced degranulation utilizing peanut-allergic patient sera and peanut protein extract.
Ladics GS; van Bilsen JH; Brouwer HM; Vogel L; Vieths S; Knippels LM
Regul Toxicol Pharmacol; 2008 Aug; 51(3):288-94. PubMed ID: 18534732
[TBL] [Abstract][Full Text] [Related]
12. Systemic administration of an Fcgamma-Fc(epsilon)-fusion protein in house dust mite sensitive nonhuman primates.
Van Scott MR; Mertsching E; Negrou E; Miles J; Stallings HW; Graff C; Kehry MR
Clin Immunol; 2008 Sep; 128(3):340-8. PubMed ID: 18583194
[TBL] [Abstract][Full Text] [Related]
13. Human IgE receptor alpha-chain IgG chimera blocks passive cutaneous anaphylaxis reaction in vivo.
Haak-Frendscho M; Ridgway J; Shields R; Robbins K; Gorman C; Jardieu P
J Immunol; 1993 Jul; 151(1):351-8. PubMed ID: 7686940
[TBL] [Abstract][Full Text] [Related]
14. A chimeric human-cat Fcgamma-Fel d1 fusion protein inhibits systemic, pulmonary, and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d1, the major cat allergen.
Terada T; Zhang K; Belperio J; Londhe V; Saxon A
Clin Immunol; 2006 Jul; 120(1):45-56. PubMed ID: 16473552
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein.
Eggel A; Buschor P; Baumann MJ; Amstutz P; Stadler BM; Vogel M
Allergy; 2011 Jul; 66(7):961-8. PubMed ID: 21272035
[TBL] [Abstract][Full Text] [Related]
16. Utilizing Fcepsilon-Bak chimeric protein for studying IgE-FcepsilonRI interactions.
Belostotsky R; Lorberboum-Galski H
Clin Immunol; 2004 Jan; 110(1):89-99. PubMed ID: 14962800
[TBL] [Abstract][Full Text] [Related]
17. A novel bispecific DARPin targeting FcγRIIB and FcεRI-bound IgE inhibits allergic responses.
Zellweger F; Gasser P; Brigger D; Buschor P; Vogel M; Eggel A
Allergy; 2017 Aug; 72(8):1174-1183. PubMed ID: 27997998
[TBL] [Abstract][Full Text] [Related]
18. "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling.
Saxon A; Kepley C; Zhang K
J Allergy Clin Immunol; 2008 Feb; 121(2):320-5. PubMed ID: 18086492
[TBL] [Abstract][Full Text] [Related]
19. Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge.
Christensen LH; Holm J; Lund G; Riise E; Lund K
J Allergy Clin Immunol; 2008 Aug; 122(2):298-304. PubMed ID: 18572230
[TBL] [Abstract][Full Text] [Related]
20. Houttuynia cordata water extract suppresses anaphylactic reaction and IgE-mediated allergic response by inhibiting multiple steps of FcepsilonRI signaling in mast cells.
Han EH; Park JH; Kim JY; Jeong HG
Food Chem Toxicol; 2009 Jul; 47(7):1659-66. PubMed ID: 19394399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
